Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 June;51(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 June;51(2):182-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

ORIGINAL ARTICLES  MOLECULAR IMAGING IN PHARMACOLOGY 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 June;51(2):182-8

Copyright © 2007 EDIZIONI MINERVA MEDICA

language: English

99mTc-HYNIC Annexin-V imaging of tumors and its relationship to response to radiotherapy and/or chemotherapy

Rottey S. 1, Loose D. 2, Vakaet L. 3, Lahorte C. 4, Vermeersch H., Van Belle S. 1, Van De Wiele C. 5

1 Division of Medical Oncology University Hospital Ghent, Belgium 2 Department of Head and Neck Surgery University Hospital Ghent, Belgium 3 Division of Radiotherapy University Hospital Ghent, Belgium 4 Department of Radiopharmacy Ghent University, Ghent, Belgium 5 Division of Nuclear Medicine University Hospital Ghent, Belgium


PDF


Aim. The aim of this study was to report on the relationship between preradiotherapy and prechemotherapy 99mTc-HYNIC Annexin-V tumor uptake values, reflecting ongoing apoptosis, and outcome to radiotherapy and/or chemotherapy.
Methods. Twenty-three cancer patients underwent staging examinations and a 99mTc-HYNIC Annexin-V scintigraphy and subsequent radiotherapy and/or chemotherapy. Tumor-to-background ratios derived from tomographic 99mTc-HYNIC Annexin-V images were related to treatment outcome as assessed by RECIST criteria.
Results. Six patients underwent radiotherapy or radiochemotherapy: 4 exhibited response to treatment, 1 had stable, and 1 progressive disease. Corresponding tumor-to-background ratio’s were respectively ≥2.3 (in responders), 1.2 in the patient presenting with stable disease and 1 in the patient presenting with progressive disease. Seventeen patients were treated by chemotherapy alone: 8 were progressive, 1 patient presented with stable disease and 8 responded to treatment. In 1/8 progressive patients a tumor-to-background ratio of 1.4 was found, the others showed no uptake. In the patient presenting with stable disease a ratio of 0.1 was found. In the 8 responders, 7 patients had a tumor-to-background ratio ≥1.3 whereas in 1 patient a ratio of 0.3 was found. Tumor-to-background ratios in responders (complete plus partial) (median 2.5, range: 0.3-4.2) were significantly higher when compared to those obtained in non-responders (stable plus progressive disease) (median 1, range: 0.1-1.4) (P<0.001).
Conclusion. The findings presented suggest that 99mTc-HYNIC Annexin-V pretreatment uptake may be useful to predict response to chemo- and radiotherapy.

top of page